dexrazoxane has been researched along with Cardiomyopathies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdo, VB; Ashour, RH; El Beltagy, HM; El Fatah, DSA; El-Karef, A; Elkatary, RG | 1 |
| Adamcová, M; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Roh, J; Šimůnek, T; Skalická, V; Štěrba, M; Štěrbová-Kovaříková, P | 1 |
| Block, J; Brickler, M; Burke, MJ; Hoffmann, R; McFadden, V; Pan, A; Schloemer, NJ; Simpson, P; Tower, RL | 1 |
| Johnson, R; Kappo, AP; Louw, J; Muller, CJF; Shabalala, S | 1 |
| Bjelogrlic, SK; Djuricic, SM; Lukic, ST | 1 |
| He, LH; Hu, KY; Jia, ZR; Li, SR; Li, XJ; Mao, J; Tian, W; Wang, DW; Yang, Y; Zhang, W | 1 |
| Armenian, SH; Asselin, BL; Borowitz, MJ; Camitta, BM; Chen, L; Devidas, M; Franco, VI; Hutchison, RE; Lipshultz, SE; Pullen, J; Ravindranath, Y | 1 |
| Akabuogu, EU; Phyu, SM; Smith, TA | 1 |
| Al-Harbi, NO | 1 |
| Abdel-Qadir, H; Amir, E; Fazelzad, R; Lee, DS; Ong, G; Thavendiranathan, P; Tomlinson, G | 1 |
1 review(s) available for dexrazoxane and Cardiomyopathies
| Article | Year |
|---|---|
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Cardiomyopathies; Clinical Trials as Topic; Dexrazoxane; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Network Meta-Analysis; Prenylamine; Ventricular Dysfunction, Left | 2017 |
1 trial(s) available for dexrazoxane and Cardiomyopathies
| Article | Year |
|---|---|
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Grou
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Doxorubicin; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Troponin T | 2016 |
8 other study(ies) available for dexrazoxane and Cardiomyopathies
| Article | Year |
|---|---|
Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice.
Topics: Animals; Antineoplastic Agents; Cardiomyopathies; Dexrazoxane; Doxorubicin; Male; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2023 |
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Topics: Animals; Anthracyclines; Cardiomyopathies; Cardiotoxicity; Cell Line, Tumor; Dexrazoxane; DNA Topoisomerases, Type II; Heart; HL-60 Cells; Humans; Male; Models, Animal; Myocardium; Myocytes, Cardiac; Protective Agents; Rabbits; Rats; Rats, Wistar; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes.
Topics: Adolescent; Anthracyclines; Cardiomyopathies; Cardiotonic Agents; Child; Child, Preschool; Dexrazoxane; Heart Function Tests; Humans; Infant; Leukemia, Myeloid, Acute; Survival Rate; Young Adult | 2017 |
Aspalathin Reverts Doxorubicin-Induced Cardiotoxicity through Increased Autophagy and Decreased Expression of p53/mTOR/p62 Signaling.
Topics: Animals; Apoptosis; Autophagy; Cardiomyopathies; Cell Line; Cell Line, Tumor; Chalcones; Dexrazoxane; Doxorubicin; Humans; Oxidative Stress; Rats; Signal Transduction; Tumor Suppressor Protein p53 | 2017 |
Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotonic Agents; Cyclophosphamide; Dexrazoxane; Doxorubicin; Drug Combinations; Female; Mice; Mice, Inbred BALB C; Myocardium | 2013 |
[Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiomyopathies; Cardiotoxicity; Cyclooctanes; Dexrazoxane; Doxorubicin; Heart; Lignans; Myocardium; Polycyclic Compounds; Rats; Rats, Sprague-Dawley | 2014 |
Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cardiomyopathies; Cardiotonic Agents; Cardiovascular Agents; Carvedilol; Cell Line, Tumor; Cell Survival; Dexrazoxane; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Enalapril; Female; Fluorodeoxyglucose F18; Humans; Metformin; Propanolamines; Radionuclide Imaging; Radiopharmaceuticals; Receptor, ErbB-2; Trastuzumab | 2016 |
Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Gene Expression; Male; Oligopeptides; Oxidative Stress; Rats, Wistar; Ventricular Myosins | 2016 |